PT001
Pre-clinical- Indications
- Cancer
Company intelligence / Profile preview
Protect Animal Health
Taiwanlinkedin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Protect Animal Health is developing PT001, a proprietary PD-L1 + CTLA-4 cancer immunotherapy vaccine for dogs that is currently in early clinical trials. The company is making significant progress in canine cancer treatment by leveraging Nobel Prize-winning immune checkpoint therapy mechanisms.
- Therapeutic areas
- OncologyCardiovascularInfectious Diseases
- Modalities
- Therapeutic vaccinesFusion proteinsAntibodies
- Industry
- Veterinary
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
DotBio
Beyond the preview
Go deeper on Protect Animal Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protect Animal Health.